This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IDEXX Laboratories CEO Presents At 30th Annual JP Morgan Healthcare Conference (Transcript)

IDEXX Laboratories, Inc. (IDXX)

30th Annual JP Morgan Healthcare Conference

January 09, 2012, 17:30 p.m. ET

Executi ve

Jon Ayers - Chairman, President and CEO

Merilee Raines - Corporate VP and CFO


Unidentified Analyst

We are going to go ahead and get started. (inaudible) and Diagnostics team. It's my pleasure to introduce our next company, IDEXX Labs. For anyone that’s in the breakout it's going to be across the hall in the Georgia room and let me turn it over to Jon Ayers, to tell you little bit more about the story.

Jon Ayers

Thank you very much. I’m also joined here by Merilee Raines, our Chief Financial Officer, and Merilee and I will be in the breakout room afterwards, really happy to have you all here at the JP Morgan Healthcare Conference.

First of course be familiar with our Safe Harbor statement. Let me change a pace. I hear there are always hundreds of companies presenting at the JP Morgan Healthcare Conference, and all of them but us are I think presenting on the human species and so we are switching track here and talking about some other mammals, that would be dogs and cats and livestock and poultry, generally animal health, a non-human. These are attractive global markets where of course, our big business is in pet healthcare, but we also have other animal health, livestock, and poultry diagnostics. We are big innovator, we are going to talk a little bit about that in both diagnostic and information technology and we had a really great track record over the last couple of decades of consistent top line growth even through the great recession and earnings growth.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs